Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MPSK3169A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | - |
| D | EXPERIMENTAL | - |
| E | EXPERIMENTAL | - |
| F | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MPSK3169A | DRUG | Dose regimen A, repeating subcutaneous injections every 4 weeks |
| Placebo | DRUG | Repeating subcutaneous injections of placebo every 4 weeks |
Inclusion Criteria: * Use of a standard-of-care statin at a stable dose, or intolerance of statins, without use of other lipid modifying therapies * Fasting LDL cholesterol 90-250 mg/dL on the statin regimen above And at least one of the following: * Coronary heart disease (CHD) with a history of...
MPSK3169A is an investigational small molecule being studied for the treatment of Coronary Heart Disease. It is being developed by Roche Holding AG (RHHBY) and is currently in Phase 2 clinical development. The drug has been evaluated in a completed Phase 2 trial involving patients with coronary heart disease or at high risk of the condition.
MPSK3169A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational small molecule for the treatment of Coronary Heart Disease. The drug is currently in Phase 2 development.
MPSK3169A is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 2 trial has been completed, evaluating the safety and efficacy of MPSK3169A in patients with Coronary Heart Disease or at high risk of the condition.
MPSK3169A has one completed clinical trial, NCT01609140, a Phase 2 study of its safety and efficacy in patients with Coronary Heart Disease or at high risk of the condition. The trial enrolled 248 participants across multiple countries, including the United States, Canada, Germany, and others.
MPSK3169A is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Coronary Heart Disease. A Phase 2 trial has been completed, but the drug has not yet received regulatory approval for any indication.
MPSK3169A is a small molecule being developed by Roche Holding AG for the treatment of Coronary Heart Disease. The specific molecular target of MPSK3169A has not been disclosed in available information. It is currently in Phase 2 clinical development, with one completed trial evaluating its safety and efficacy.